Jun 22, 2020
FDA Accepts Supplemental Biologics License Application (sBLA) for BOTOX® (onabotulinumtoxinA) for the Treatment of Pediatric Patients with Neurogenic Detrusor Overactivity
Feb 18, 2020
Women's Excellence Offers Minimally Invasive Treatment Options for Urinary Incontinence
May 03, 2019
AUA and SUFU Release New Clinical Guideline on Urinary Incontinence after Prostate Treatment
Dec 13, 2018
Women's Excellence Offers In-Office Testing for Bladder Control Problems like Overactive Bladder and Stress Incontinence
Jul 30, 2018
BlueWind Medical Appoints Dr. Roger R. Dmochowski, MD, MMHC, as Chief Medical Officer
Apr 23, 2018
LABORIE Medical Technologies and Cogentix Medical Announce Completion of Acquisition of Cogentix Medical by LABORIE Medical Technologies
Mar 12, 2018
LABORIE Medical Technologies to acquire Cogentix Medical Inc., for $214 million
Feb 28, 2018
Urovant Sciences Announces Upcoming Presentations of Data from Phase 2b Trial of Vibegron in Patients with Overactive Bladder
Dec 06, 2017
Cogentix Medical Announces Palmetto GBA Extends Medicare Coverage on Urgent® PC
Sep 12, 2017
U.S. FDA Accepts for Review Astellas' Supplemental New Drug Application for mirabegron for Use in Combination with solifenacin succinate 5 mg for the Treatment of Overactive Bladder
Sep 01, 2017
Urinary Catheters Market Worth 2.19 Billion USD by 2022
Aug 21, 2017
Urodynamic Equipment and Consumables Market Analysis 2014 - 2025
Aug 14, 2017
Global Urodynamic Devices Market - Analysis, Technologies & Forecasts to 2021 - Key Vendors are Laborie, CooperSurgical, Verathon & Albyn Medical
Jul 27, 2017
Overactive Bladder Treatment Market Worth 4.19 Billion USD by 2022